Showing results (501-510 of 561) with videos related to

Sort By:
Pageof 57
The Lancet. Oncology|September 30, 2017
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trialDaniel V T Catenacci, Niall C Tebbutt, Irina Davidenko, et al.
Lancet (London, England)|November 30, 2015
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trialAndrea Wang-Gillam, Chung-Pin Li, György Bodoky, et al.
European Journal of Cancer (Oxford, England : 1990)|October 27, 2019
DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trialRaghav Sundar, Alvin Ng, Hermioni Zouridis, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2018
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trialLi-Tzong Chen, Jens T Siveke, Andrea Wang-Gillam, et al.
The Lancet. Oncology|March 6, 2017
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trialGary Middleton, Daniel H Palmer, William Greenhalf, et al.
The Lancet. Oncology|February 5, 2020
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trialJohn A Bridgewater, Siân A Pugh, Tom Maishman, et al.
Nature Cancer|February 5, 2022
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE studyAnnika Fendler, Lewis Au, Scott T C Shepherd, et al.
British Journal of Cancer|July 20, 2016
Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC studySiân A Pugh, Megan Bowers, Alexandre Ball, et al.
Academic Radiology|August 13, 2013
Noninvasive phosphorus magnetic resonance spectroscopic imaging predicts outcome to first-line chemotherapy in newly diagnosed patients with diffuse large B-cell lymphomaFernando Arias-Mendoza, Geoffrey S Payne, Kristen Zakian, et al.
Targeted Oncology|December 27, 2015
Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based TherapyEric Van Cutsem, Florence Joulain, Paulo M Hoff, et al.
Pageof 57